1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends

Genocea Biosciences, Inc. - Product Pipeline Review - 2015

  • August 2015
  • 30 pages
  • Global Markets Direct
Report ID: 1593134

Summary

Table of Contents

Search Inside

Genocea Biosciences, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Genocea Biosciences, Inc. - Product Pipeline Review - 2015’, provides an overview of the Genocea Biosciences, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genocea Biosciences, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Genocea Biosciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Genocea Biosciences, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Genocea Biosciences, Inc.’s pipeline products

Reasons to buy

- Evaluate Genocea Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Genocea Biosciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Genocea Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Genocea Biosciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genocea Biosciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Genocea Biosciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2017

  • $ 3500
  • Company report
  • June 2017
  • by Global Markets Direct

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2017 Summary According to the recently published report 'T Cell Surface Glycoprotein CD4 - Pipeline Review, ...

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017

  • $ 3500
  • Company report
  • June 2017
  • by Global Markets Direct

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017 Summary Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are ...

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2017

  • $ 3500
  • Company report
  • June 2017
  • by Global Markets Direct

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2017 Summary Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important ...

Mumps - Pipeline Review, H1 2017

February 2017 $ 2000

Plague - Pipeline Review, H1 2017

February 2017 $ 2000

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.